Fermion Oy Fermion Oy

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Wockhardt","sponsor":"ICICI Prudential","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"Wockhardt Raises Rs 480 Crore to Pare Debt, Fund Drug Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Zidebactam

    Menu

    Zidebactam

    DEVELOPMENTS

    PRICE INFORMATION

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Wockhardt

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Wockhardt Raises Rs 480 Crore to Pare Debt, Fund Drug Trial

              Details:

              The net proceeds will be used to fund the clinical trial for WCK 5222, a combination of cefepime and the novel β-lactam enhancer (BLE) zidebactam, currently being studied in a global Phase 3 trial in complicated urinary tract infection.

              Lead Product(s): Cefepime,Zidebactam

              Therapeutic Area: Infections and Infectious Diseases Product Name: WCK 5222

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: ICICI Prudential

              Deal Size: $57.5 million Upfront Cash: Undisclosed

              Deal Type: Private Placement March 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.
              Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.
              Post Enquiry
              POST ENQUIRY